UiPath's consensus analyst price target has been modestly increased to $13.71 per share following the latest updates. This shift comes as experts weigh recent product announcements and revenue beats, ...
Zacks.com on MSN
UiPath (PATH) Outperforms Broader Market: What You Need to Know
UiPath (PATH) closed at $14.37 in the latest trading session, marking a +1.2% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.21%. On the other hand, the ...
5don MSN
Why UiPath Jumped 19% in October
UiPath announced a number of new collaborations and products at its Fusion conference. Time magazine named its agentic ...
According to MarketsandMarkets™, the global Document AI Market size is projected to grow from USD 14.66 billion in 2025 to ...
Strategic AI partnerships and Maestro orchestration platform position UiPath for enterprise adoption. Read why PATH presents ...
UiPath's AI agent momentum is fueling margin expansion and a re-acceleration of growth. Click here to read an analysis of ...
UiPath’s Chief People Officer, Agi Garaba, is re-thinking how to measure progress when automation becomes part of everyday ...
Zacks Investment Research on MSN
UiPath, Inc. (PATH) is Attracting Investor Attention: Here is What You Should Know
UiPath (PATH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
TipRanks on MSN
UiPath price target raised to $14 from $12 at RBC Capital
RBC Capital raised the firm’s price target on UiPath (PATH) to $14 from $12 and keeps a Sector Perform rating on the shares as part of a broader ...
Vir Biotechnology, Inc. , today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional execution across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback